Shift in Global R&D Trend
$350.00
The report on the shift in R&D trends from small molecules to large molecules outlines the transformative changes in R&D paradigms. It highlights the increasing focus on biologics, such as monoclonal antibodies and gene therapies, which offer targeted and effective treatments for complex diseases.
Key sections discuss the scientific advancements facilitating this transition, the implications for pharmaceutical companies in terms of investment and regulatory strategies, and the R&D pipeline. Additionally, the report captures the impact of Off-patent drugs in the market, emphasizing the need for innovation in processes and technologies to support this shift.
| 1.0 | Shift in R&D Trend From Small molecule to Large molecule |
| 1.1 | Global Life Sciences | Sector Understanding | Sample Companies |
| 1.2 | Revenue & R&D Spend Understanding from sample companies |
| 1.3 | R&D Spend on Large molecules by Companies |
| 1.4 | R&D Spend on Small molecules by Companies |
| 1.5 | R&D Pipeline | Clinical Trial Data |
| 1.6 | R&D Drug Pipeline | Phase I to III | By Companies & Molecule Category |
| 2.0 | Small Molecule Category – R&D Pipeline & Off-Patent Drugs |
| 2.1 | R&D Spend on Chemical / Synthetic Drugs by Companies |
| 2.2 | R&D Spend on Chemical / Synthetic Drugs by Research Area |
| 2.3 | R&D Drug Pipeline by Therapeutic Area | Phases I to III | 500+ Drugs |
| 2.4 | R&D Drug Pipeline Phase I to III | By Companies |
| 2.5 | Off – Patent Drugs Summary | For 2022 – 2031 | 430+ drugs |
| 2.6 | Off – Patent Drugs Summary | By Therapeutic Areas |
| 3.0 | Key Takeaways |
| 3.10 | Forward Looking Statements |
